Kymera posts Q3 net loss $62.5M; initiates STAT6 degrader Phase 1; shifts focus to immunology

Kymera Therapeutics, Inc.

2024-Q3 EPS reported -$2.09 revenue$39,678,000

Net loss $62.5M in Q3 2024 vs $52.9M in Q3 2023; collaboration revenue $3.7M from Sanofi.
Initiated Phase 1 dosing for KT-621 (STAT6 degrader); Phase 1 data expected H1 2025.
Sanofi expands KT-474 (IRAK4) Phase 2 HS/AD trials to dose-ranging Phase 2b; primary completion mid-2026.
Selected KT-295 (TYK2 degrader) as development candidate; Phase 1 start in H1 2025.
Cash $911M as of Sep 30, 2024; runway into mid-2027; will only advance oncology with partner.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.